A number of research firms have changed their ratings and price targets for Scholar Rock (NASDAQ: SRRK):

  • 5/18/2019 – Scholar Rock was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company’s product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States. “
  • 5/15/2019 – Scholar Rock had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $27.00 price target on the stock.
  • 5/9/2019 – Scholar Rock was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company’s product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States. “
  • 5/7/2019 – Scholar Rock was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 4/16/2019 – Scholar Rock was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company’s product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States. “
  • 4/10/2019 – Scholar Rock was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company’s product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States. “

NASDAQ SRRK traded down $1.53 during mid-day trading on Thursday, hitting $19.03. The company’s stock had a trading volume of 502 shares, compared to its average volume of 83,304. Scholar Rock Holding Corp has a twelve month low of $13.09 and a twelve month high of $30.00. The company has a current ratio of 4.76, a quick ratio of 4.76 and a debt-to-equity ratio of 0.05. The company has a market cap of $556.26 million and a P/E ratio of -6.04.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.08. The business had revenue of $3.11 million during the quarter, compared to analyst estimates of $5.05 million. Sell-side analysts predict that Scholar Rock Holding Corp will post -1.83 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Federated Investors Inc. PA grew its position in Scholar Rock by 26.5% in the 1st quarter. Federated Investors Inc. PA now owns 3,577 shares of the company’s stock valued at $67,000 after purchasing an additional 750 shares during the period. BlackRock Inc. boosted its holdings in Scholar Rock by 0.4% during the 4th quarter. BlackRock Inc. now owns 369,810 shares of the company’s stock worth $8,494,000 after acquiring an additional 1,447 shares during the last quarter. Citigroup Inc. boosted its holdings in Scholar Rock by 122.8% during the 1st quarter. Citigroup Inc. now owns 3,970 shares of the company’s stock worth $74,000 after acquiring an additional 2,188 shares during the last quarter. BNP Paribas Arbitrage SA purchased a new position in Scholar Rock during the 1st quarter worth $59,000. Finally, Northern Trust Corp boosted its holdings in Scholar Rock by 5.7% during the 4th quarter. Northern Trust Corp now owns 69,825 shares of the company’s stock worth $1,604,000 after acquiring an additional 3,791 shares during the last quarter. 54.81% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.

Read More: Should I follow buy, hold and sell recommendations?

Receive News & Ratings for Scholar Rock Holding Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock Holding Corp and related companies with MarketBeat.com's FREE daily email newsletter.